# Evolus, Inc. (EOLS)

> Source: Nexqual · https://nexqual.com/EOLS · data as of 2026-10-15 20:00 UTC · cite as "Nexqual, Evolus, Inc. (EOLS), nexqual.com/EOLS" · informational, not investment advice.

**Price:** USD 7.57 (+4.85% on the day) · last close of Oct 15, 2026; US market closed, not a live price. Prev close 7.22 · day 7.23–7.71 · 52w 3.86–9.31 · market cap $500M · NGM

## Key facts
- Analysts: Buy (mean 2.00 on a 1–5 scale) (6 analysts), mean target USD 15 (range 12–20).
- Total return with dividends: 1Y +20.2% vs S&P 500 +18.1%; 5Y -1.3% vs S&P 500 +85.1%.
- Next earnings: 2026-11-04, EPS estimate USD -0.07, revenue estimate $77.6M.

## Analysts
Consensus Buy (mean 2.00 on a 1–5 scale), 6 analysts; mean target USD 15 (low 12, high 20).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-25 | HC Wainwright & Co. | Reiterated | Buy | $13 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-16) | 5Y (from 2021-10-11) |
|---|---|---|
| Total return | +20.2% | -1.3% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | +20.2% | -0.3% |
| Volatility (annualized) | 64.4% | 63.8% |
| Max drawdown | -46.5% (Nov 2025→Mar 2026) | -77.1% (Sep 2024→Mar 2026) |

## Peers (Drug Manufacturers - Specialty & Generic)
BHC (Bausch Health Companies Inc.) USD 6.31 +7.13% · HCM (HUTCHMED (China) Limited) USD 13.94 +3.26% · LQDA (Liquidia Corporation) USD 34.78 +29.73% · AMLX (Amylyx Pharmaceuticals, Inc.) USD 27.65 +2.98% · INDV (Indivior Pharmaceuticals, Inc.) USD 33.62 -5.08% · RGC (Regencell Bioscience Holdings L) USD 9.52 +16.24%

## More
Full page: https://nexqual.com/EOLS · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt